<DOC>
	<DOCNO>NCT01941290</DOCNO>
	<brief_summary>For majority Coronary Artery Disease ( CAD ) , treatment Percutaneous Transluminal Coronary Angioplasty ( PTCA ) provide high initial procedural success . However , medium long-term complication range rather immediate elastic recoil vessel contraction longer process like smooth muscle cell proliferation excessive production extra cellular matrix , thrombus formation atherosclerotic change like restenosis angiographic re-narrowing . The reported incidence restenosis PTCA range 30 % -50 % . Such rate recurrence serious economic consequence . Bare Metal Stents ( BMS ) , design address limitation PTCA , reduce angiographic clinical restenosis rate de novo lesion compare PTCA alone decrease need CABG . BMS substantially reduce incidence abrupt artery closure , restenosis still occur 20 % -40 % case , necessitate repeat procedure . The invention Drug Eluting Stents ( DES ) significantly improve principle BMS add antiproliferative drug ( directly immobilize stent surface release polymer matrix ) , inhibit neointimal hyperplasia . The introduction DES greatly reduce incidence restenosis result good safety profile compare BMS systemic drug administration . These advantage low cost compare surgical intervention make DES attractive option treat coronary artery disease . An interesting group analysis result diabetic patient . It conclude incidence nonocclusive occlusive restenosis higher diabetic subject stenting judge comparison historical control subject . Results implicate accelerate restenosis consequence diabetes cause increase mortality PCI diabetic patient . Therefore observational registry design clinical evaluation Orsiro LESS diabetic subject ( Diabetic patient type 1 2 ) require coronary revascularization Drug Eluting Stents ( DES ) . Results contribute collection clinical evidence clinical performance safety Orsiro Drug Eluting Stent System daily clinical practice .</brief_summary>
	<brief_title>BIOFLOW III Asia Registry</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Inclusion Criteria Diabetes Mellitus : Known Diabetic Pharmacological treatment . ACS NSTEMI document Hb A1c &gt; 7 % , even Pharmacological treatment diabetes . Patient Symptomatic coronary artery disease Target lesion must de novo lesion locate native coronary artery reference vessel diameter ≥2.25 mm &amp; ≤4.00 mm , lesion length ≤40 mm visual estimate Patient receive 3 stent 2 stent per artery . Target lesion must major coronary artery branch visually estimate stenosis ≥50 % &amp; &lt; 100 % TIMI flow≥1 . Subject provide sign informed consent data release Subject geographically stable willing comply protocol require follow ups Subject ≥ 18 year age Pregnant and/or breastfeed female intend become pregnant period registry Untreatable intolerance aspirin , clopidogrel , ticlopidine , heparin anticoagulation / antiplatelet therapy require PCI , stainless steel , Sirolimus contrast medium Planned surgery within 6 month PCI unless dual antiplatelet therapy maintain Currently participate another study primary endpoint reach yet If subject high probability procedure predilatation , stent implantation post dilatation require time index procedure treatment target vessel ( e.g . atherectomy , cut balloon brachytherapy ) . Patients admit treatment Diabetic ketoacidosis ≥ 2 time past Six month ( Brittle Diabetics ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>International</keyword>
	<keyword>Multicenter</keyword>
	<keyword>Observational registry</keyword>
	<keyword>Orsiro Drug Eluting Stents ( DES )</keyword>
	<keyword>Stenting</keyword>
	<keyword>Treatment Coronary Artery Disease</keyword>
	<keyword>Coronary Revascularization</keyword>
	<keyword>Percutaneous Coronary Intervention ( PCI )</keyword>
	<keyword>Diabetes Mellitus Type 1</keyword>
	<keyword>Diabetes Mellitus Type 2</keyword>
	<keyword>STEMI</keyword>
	<keyword>NSTEMI</keyword>
	<keyword>Ischemia</keyword>
	<keyword>Angina</keyword>
	<keyword>Subgroups</keyword>
	<keyword>Acute Myocardial Infarction</keyword>
	<keyword>Small Vessels</keyword>
	<keyword>Chronic Total Occlusion</keyword>
</DOC>